Juno Therapeutics (JUNO) Reports In-Line Q1 EPS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. SPY
2. PLTR
3. MSFT
4. TMUS
5. LBRX
6. BMY
7. MRK
8. TRAX
9. LMT
10. MIRM

Go back to Juno Therapeutics (JUNO) Reports In-Line Q1 EPS

Juno Therapeutics Reports First Quarter 2017 Financial Results

May 4, 2017 4:06 PM EDT

Initiated five trials with new binders, technologies, and targets

2017 cash burn and operating burn guidance reaffirmed

Added key talent to leadership team

Eleven product candidates in clinical trials against eight different targets

Strong cash position of $850.7 million

Conference call today at 5:00 p.m. Eastern Time

SEATTLE--(BUSINESS WIRE)-- Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today reported financial results and business highlights for the... More